secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akero Therapeutics, Inc. (—)
CIK:        0001744659
Form:       8-K
Filed at:   2025-10-09T23:59:59+00:00
Accession:  0001193125-25-235919
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akero to be acquired by Novo Nordisk for up to $5.2B; $54/share cash + $6 CVR
-----------------------------------------------------------------------------

- Shareholders get $54.00 cash per share at closing (equity value ~$4.7B) plus a CVR worth up to $6.00 per share if FDA approves efruxifermin for MASH-cirrhosis by June 30, 2031.
- Total potential equity value ~$5.2B; upfront cash represents a 19% premium to 30-day VWAP and 42% to pre-speculation close on May 19, 2025.
- Merger expected to close around year-end 2025, subject to Akero shareholder vote, antitrust clearance, and other conditions.
- Termination fees: Akero pays $165M under certain circumstances; Novo Nordisk pays $185M reverse fee if antitrust conditions not met.
- Board adopted forum selection bylaw amendment on October 8, 2025; transaction will supplement Novo Nordisk's GLP-1 metabolic portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1744659/000119312525235919/0001193125-25-235919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1744659/000119312525235919/d42650d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-235919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer